Exocrine Pancreatic Insufficiency (EPI) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Exocrine Pancreatic Insufficiency (EPI) Market is segmented by Therapies (Pancreatic exocrine replacement therapies (PERT), Nutritional Therapy (Dietary supplements)), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Exocrine Pancreatic Insufficiency (EPI) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Exocrine Pancreatic Insufficiency Industry Overview

The exocrine pancreatic insufficiency market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Digestive Care, AbbVie, Nestle, Alcresta Therapeutics, First Wave BioPharma, Chiesi Pharmaceuticals, Vivus, Aimmune Therapeutics, PerseoPharma, Codexis, Synspira Therapeutics, among others.

Exocrine Pancreatic Insufficiency Market Leaders

  1. Digestive Care

  2. AbbVie

  3. Nestle

  4. Alcresta Therapeutics

  5. First Wave BioPharma

  6. *Disclaimer: Major Players sorted in no particular order
Picture70.png

Global Exocrine Pancreatic Insufficiency (EPI) Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?